Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07281001
What this trial is testing

Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

Who this might be right for
HER2-positive Breast CancerTrastuzumab Deruxtecan
Blokhin's Russian Cancer Research Center 60
Large-scale testing (Phase 3)Ended earlyNCT02213744
What this trial is testing

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHER2 Positive Breast Cancer
Merrimack Pharmaceuticals 113
Testing effectiveness (Phase 2)Looking for participantsNCT05635487
What this trial is testing

SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Who this might be right for
HER2-positive Breast Cancer
Shengjing Hospital 65
Large-scale testing (Phase 3)Active Not RecruitingNCT07386938
What this trial is testing

The Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
R-Pharm 246
Post-approval studies (Phase 4)Not Yet RecruitingNCT07589699
What this trial is testing

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Who this might be right for
Breast CancerHER2-positive Breast CancerEarly-stage Breast Cancer+1 more
The First Affiliated Hospital with Nanjing Medical University 59
Not applicableNot Yet RecruitingNCT07187752
What this trial is testing

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Who this might be right for
Breast Cancer
Shandong Cancer Hospital and Institute 1,039
Large-scale testing (Phase 3)Looking for participantsNCT06313086
What this trial is testing

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 442
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07836257
What this trial is testing

A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd

Who this might be right for
Breast Cancer
Fujian Medical University 28
Not applicableStudy completedNCT00898898
What this trial is testing

Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 2,837
Not applicableStudy completedNCT04756921
What this trial is testing

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Who this might be right for
HER2-positive Breast Cancer
Biyun Wang, MD 30
Testing effectiveness (Phase 2)Ended earlyNCT00130507
What this trial is testing

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 14
Large-scale testing (Phase 3)Looking for participantsNCT07377643
What this trial is testing

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 540
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06548178
What this trial is testing

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Fudan University 242
Large-scale testing (Phase 3)Not Yet RecruitingNCT05388500
What this trial is testing

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

Who this might be right for
HER2-positive Breast Cancer
Institut de cancérologie Strasbourg Europe 800
Large-scale testing (Phase 3)UnknownNCT04665986
What this trial is testing

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 50
Large-scale testing (Phase 3)Study completedNCT00047255
What this trial is testing

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 263
Early research (Phase 1)Ended earlyNCT00634088
What this trial is testing

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
R-Pharm 13
Early research (Phase 1)Study completedNCT03451162
What this trial is testing

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 14
Early research (Phase 1)Ended earlyNCT03429101
What this trial is testing

Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Spectrum Pharmaceuticals, Inc 6
Testing effectiveness (Phase 2)UnknownNCT04858516
What this trial is testing

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Who this might be right for
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
Guangdong Provincial People's Hospital 57
Next Page